Education
About Us
Working with TipRanks
Follow Us
MapLight Therapeutics, Inc. (MPLT)
NASDAQ:MPLT
MPLT Stock Chart & Stats
$17.25
--
Market closed
$17.25
--
Day’s Range― - ―
52-Week Range$12.24 - $21.55
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.63K
Market Cap
$814.90M
Enterprise Value-$43.96M
Total Cash (Recent Filing)$227.17M
Total Debt (Recent Filing)$6.01M
Price to Earnings (P/E)―
Beta0.40
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding45,373,030
10 Day Avg. Volume205,334
30 Day Avg. Volume401,626
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-9.55
Enterprise Value/Market Cap-0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit100.37
Enterprise Value/Ebitda0.42
Forecast
1Y Price Target
$31.00Price Target Upside79.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.69
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt relative to equity gives durable financial flexibility for a clinical-stage biotech. It supports continued R&D investment, reduces short-term solvency risk, and allows the company to fund operations or opportunistic partnerships without being forced into distressed financing.
Material Capital Raise And RunwayA sizable raise materially extends operational runway through stated 2027 timeframe. This reduces immediate dilution pressure, funds multiple Phase 2 programs, and increases the probability management can reach key clinical readouts before needing additional financing, a durable support for execution.
Regulatory Progress: Fast Track DesignationFast Track status signals regulatory recognition of unmet need and enables more frequent FDA interactions and potential accelerated review. Structurally this can shorten development timelines and improve program de-risking if clinical data are positive, strengthening long-term program value.
Bears Say
Pre-revenue With Widening Net LossesSustained, expanding losses are a structural risk for a clinical-stage company: absent commercial revenue the business is reliant on financing markets and milestone success. Persistent widening losses increase the likelihood of future dilutive financings and place a premium on achieving clinical proof points.
Accelerating Cash Burn And Negative Free Cash FlowOperating losses are translating directly into large negative cash flows, increasing near-term financing needs. While predictable for a developer, the scale of burn reduces optionality, heightens dilution risk if trials slip, and limits ability to invest beyond core programs without new capital.
Deeply Negative Returns And Binary Program RiskDeep negative ROE shows capital deployed is not generating shareholder returns, typical for pre-commercial biotechs. Long-term value creation depends on binary clinical/regulatory outcomes; failure or delays can crystallize dilution and impair returns for existing investors over the medium term.
MapLight Therapeutics, Inc. News
MPLT FAQ
What was MapLight Therapeutics, Inc.’s price range in the past 12 months?
MapLight Therapeutics, Inc. lowest stock price was $12.24 and its highest was $21.55 in the past 12 months.
What is MapLight Therapeutics, Inc.’s market cap?
MapLight Therapeutics, Inc.’s market cap is $814.90M.
When is MapLight Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MapLight Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is MapLight Therapeutics, Inc. overvalued?
According to Wall Street analysts MapLight Therapeutics, Inc.’s price is currently Undervalued.
Does MapLight Therapeutics, Inc. pay dividends?
MapLight Therapeutics, Inc. does not currently pay dividends.
What is MapLight Therapeutics, Inc.’s EPS estimate?
MapLight Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MapLight Therapeutics, Inc. have?
MapLight Therapeutics, Inc. has 45,373,030 shares outstanding.
What happened to MapLight Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MapLight Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MPLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MapLight Therapeutics, Inc. Stock Smart Score
Company Description
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.
MPLT Stock 12 Month Forecast
Average Price Target
$31.00
▲(79.71% Upside)
Scinai Immunotherapeutics
―
Sensei Biotherapeutics
―
GRI Bio
―
Dermata Therapeutics
―
Azitra Inc
―